VA as Maintenance Therapy Post Allo-HSCT in MDS and AML
Status:
NOT_YET_RECRUITING
Trial end date:
2030-09-01
Target enrollment:
Participant gender:
Summary
The goal of this phase 2 trial is to test the safety and efficacy of Venetoclax combined with Azacytidine as Maintenance Therapy post Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndromes and Acute Myeloid Leukemia.